Octreotide Acetate for Injectable Suspension
Teva is recalling Octreotide Acetate 30 mg injection kits due to a lack of assurance of sterility.
Contact your healthcare provider or pharmacist if you have concerns about your medication. Do not use the affected product.
Recall at a glance
- Quantity recalled
- 2,200 kits
Why it was recalled
Teva Pharmaceuticals is recalling Octreotide Acetate for Injectable Suspension 30 mg kits due to a lack of assurance of sterility. The recall was initiated following quality system deficiencies identified at the contract manufacturing facility. This product was distributed nationwide.
Is mine affected?
Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular useStrength: 30 mg
| Lot code | UPC |
|---|---|
| – | 45011002 |
| 45011002, 2027 | – |
Where it was sold
Distributed nationwide.
Timeline
- Firm initiated recall
- Publicly announced
- Listed on Recall Canary
- Summary updated
Official source
Other recent recalls from Teva Pharmaceuticals USA, Inc
Editorial summary by Recall Canary · summary updated 2026-06-11 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification